Facilitating Cognitive Assessment in Primary Care for the Timely Detection of Alzheimer's Disease

Leveraging Medicare Reimbursement Mechanisms to Improve Clinical Care

Eric G. Tangalos, MD, FACP, AGSF, CMD Professor of Medicine Division of Primary Care Internal Medicine, Geriatrics and Palijative Care Mayo Clinic Rochester, Minnesota

PeerView

2

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to *The Standards* for Integrity and Independence in Accredited Continuing Education. All individuals in a for megnity and independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Disclosures

Faculty/Planner

Eric G. Tangalos, MD, FACP, AGSF, CMD Mayo Clinic Rochester, Minnesota

All of the relevant financial relationships listed have been mitigated.

Eric G. Tangalos, MD, FACP, AGSF, CMD, has a financial interest/relationship or affiliation in the form of: Consultant and/or Advisor1or Acadia Pharmaceuticals Inc.; Biogen; Eisai Co., Ltd.; and F. Hoffmann-La Roche Ltd/Genentech, Inc. Stock Shareholder in Abbvie, Inc.; Johnson & Johnson Services, Inc.; and Pfizer. Data Safety Monitoring Board for Cyclo and Prothena.

3

Planning Committee and Content/Peer Reviewers

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this accredited activity unless listed below.

4

Disclosure of Unlabeled Use

This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Housekeeping Notes

Thank you to PeerView Institute for Medical Education for providing this session, and Lilly for providing the educational grant for this program. You should have received a link to the online post-test or a printed copy of the program evaluation. In order to receive CME/MOC/NCPD/CPE/APA/IPCE credit you must complete the post-test and evaluation at the conclusion of the meeting.


Post-Test and Evaluation: PeerView.com/Alzheimers-Survey-XUM

Your evaluation of the program is very important in helping us to better meet your current and future medical education needs. We welcome your opinions and comments.

Please feel free to ask questions at the end of the presentation.




Scan this QR Code for the Post-Test & Evaluation!





Welcome and Introduction

PeerView

A Brief Review: What Is Dementia? **DSM-5** Definition¹ Acquired Acquired cognitive decline functional + in at least decline 1 domain and No other causes (eg, medical, psychiatric) stical Manual of Mental Disorders, Fifth Edition (DSM-5). American Psychiatric Association. Diagnostic and Sta Arlington, VA: American Psychiatric Association; 2013. PeerView.com







Gender, Racial, and Ethnic Disparities in AD Prevalence and Early Detection^{1,2}


- · 60% underdiagnosis of AD in high-income countries vs 90% in
- low-income countries
- · Almost two-thirds of Americans with AD are women · Older Black and Hispanic Americans are more likely than older White
- Americans to have AD or other dementias · Despite higher prevalence of AD in racial and ethnic minority populations, there is poor detection overall and large disparities
 - Racial and ethnic minorities are at higher risk of underdiagnosis (Denmark, Norway, UK, US)
 - Racial and ethnic minorities in the US (California) are less likely to be diagnosed at a mild stage and receive a less comprehensive evaluation at an early stage

PeerView.con 665. 2. ht


13

Integrating Cognitive Screening Into Clinic Visits Practical Strategies for Routine Care






















































PeerView.con



31

Communicating the Results of the Cognitive Screening

- Best practices for disclosing cognitive screening results with patients and informants
 - What symptoms are being reported by the patient or informant?
 - What are the findings from the brief cognitive screening?
 - Where does this take us next?
- Patients should NOT be told that they have dementia based on the results of a brief cognitive screen-more assessment is needed

32

Billing and Coding for Cognitive Screening^{1,2}

Medicare Annual Wellness Visit

- Initial visit: CPT G0438 - Billable for the first AWV only

 - Patient is eligible after the first 12 months of Medicare coverage For services within the first 12 months, conduct the Initial Preventive Physical Exam (IPPE), also referred to as the Welcome to Medicare Visit (G0402)
 - The patient must not have received an IPPE within the past 12 months
- Subsequent visits: CPT G0439 Non-Medicare patients may have separate billing and coding guidelines that vary by state (eg, Medi-Cal Cognitive Health Assessment: CPT 1494F)

Next Steps

- Separate from the Annual Wellness Visit, CPT 99483 is a code that can be used **once every 180 days** to perform a Cognitive Assessment and Care Plan (a more detailed cognitive evaluation)
- Many elements involved in the evaluation
- Should be scheduled within 2-3 months of the AWV

:Pwww.cms.gov/Outreach-and-Education/Medicare-Learning-Network-MLN/MLNProducts/greventive-services/medicare-wellness-visits.html. :Pwww.dementiacareaware.org/files/4097296/dca-faq-billing-R6.pdf?lmsauth=029151c47d25/413893715c265501160b56644(d PeerView.com

33

Cognitive Assessment and Care Plan Services Personalized Care for Patients With Symptoms of Cognitive Impairment

PeerView

34

Cognitive Assessment and Care Plan (CACP)¹⁻³

CACP (CPT code: 99483)

Starting in 2017, Medicare provides reimbursement to physicians and other eligible billing practitioners for a clinical visit that is dedicated to a more thorough assessment of cognitive , function and results in a written care plan

- · Only for Medicare patients who have already demonstrated signs of cognitive impairment
- CACP can be used to diagnose MCI or dementia and identify treatable causes or co-occurring conditions such as depression or anxiety
- Requires an independent informant to complete assessments related to the patient's behavior, cognition, and functioning
- Can be used once every 180 days


CACP includes 10 elements


s:Cogritive-Assessment-and Care-Planning-Services_020323.pdf. PeerView.com 1. Borson S et al. Alzheimers Dement 2017;13:1168-1173. 2. https://www.alz.org/media/Doc 3. https://www.cms.gov/cognitive.


35





CACP Components^a ended Assessment Tools Recor Coprition-focused history and obysical examination Document medical decision-making of moderate or high complexity (defined by the E/M guidelines) Functional assessment of ADLs/ADLs and decision-making capacity Formal staging of dementia using a standardized tool MMSE, MoCA, SLUMS (select of 2 Katz (ADL) and Lawton-Brody (IADL) FAST, CDR (select one) Reconciliation and review of high-risk medications Evaluate neuropsychiatric and behavioral symptoms using a standardized tool Evaluate safety, including home and driving NPI-Q, PHQ-9, GDS-short form 6 elect at least one) Safety assessment guide 8 Identify caregiver and address caregiving concerns
 9 Develop, update/revise, or review advanced care plan and palliative needs End-of-Life Checklist POLST 10 Create a written care plan Evaluation, and Management of Alzh piect-booklet-v11-082221-web.pdf tion. Cognitive Impairment and Care Planning Toolkit: https://www.alz.org/media





































CACP #9: Develop, Update/Revise, or Review Advanced Care Plan and any Palliative Needs¹⁻³

Key Questions

S et al. Alzheimers Dement 2017;13:1168-1173. 2. http: www.alz.commedia/Documentic/UC.22002. CPT-Safety-A


- · Have wishes or desires for end-of-life care been discussed?
- · Is a power of attorney in place for financial needs?
- · Is a power of attorney in place for healthcare decisions?
- · Is palliative or hospice care appropriate for the patient?


CACP #10: Preparing the Written Care Plan¹⁻³

Indicate who has responsibility for carrying out each recommended action step Specify an initial follow-up schedule	 Additional tests that need to be performed to confirm the etiology of the MCI or dementia (eg, Alzheimer's disease, vascular dementia), and whether the patient needs to be referred to a dementia specialisit Specific characteristics of the cognitive disorder (eg, type and severity of cognitive impairment) Management of any neurocognitive and neuropsychiatric symptoms
Care plan can be organized into broad components $ ightarrow$	 Comorbid medical conditions and safety management, including any changes needed to accommodate the effects of cognitive impairment
	 Caregiver stress and support needs and referrals to community-based education and support, individual or family counseling, in-home care, and legal or financial assistance, as needed
n S et al. Alzheimers Dement. 2017;13:1168-1173. 2. https://www.alz.org/media/Doc www.alz.org/media/Documents/HC-23002_CPT-Safety-Assessment_March2023.pd	

1. Bors 3. https: 50

PeerView.con





51

